The problem of choice: current biologic agents and future prospects in RA. (Q38082588)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23419427%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

The problem of choice: current biologic agents and future prospects in RA (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23419427%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23419427%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Ernest H Choy

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23419427%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Arthur F Kavanaugh

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23419427%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

language of work or name

English

0 references

publication date

19 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23419427%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Rheumatology

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23419427%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23419427%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23419427%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

154-163

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23419427%20AND%20SRC:MED&resulttype=core&format=json

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Synovial tissue heterogeneity and peripheral blood biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Synovial tissue analysis for the discovery of diagnostic and prognostic biomarkers in patients with early arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

State-of-the-art: rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Progress and promise of genome-wide association studies for human complex trait genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Role of cytokines in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Safety of biologic therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Cytokine pathways and joint inflammation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Cytokines in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Cytokines sing the blues: inflammation and the pathogenesis of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Interleukin-1, immune activation pathways, and different mechanisms in osteoarthritis and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Antagonism of the IL-6 cytokine subfamily--a potential strategy for more effective therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Tocilizumab for rheumatoid arthritis: a Cochrane systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

TNF alpha--a pivotal role in rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

The regulation of TNF signalling: what a tangled web we weave

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

IL-6 signal transduction and its physiological roles: the signal orchestration model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Local activation of STAT-1 and STAT-3 in the inflamed synovium during zymosan-induced arthritis: exacerbation of joint inflammation in STAT-1 gene-knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

NF-κB, the first quarter-century: remarkable progress and outstanding questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Although IL-6 Trans-Signaling Is Sufficient To Drive Local Immune Responses, Classical IL-6 Signaling Is Obligate for the Induction of T Cell-Mediated Autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Effector T cell plasticity: flexibility in the face of changing circumstances

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Epigenetic instability of cytokine and transcription factor gene loci underlies plasticity of the T helper 17 cell lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Late developmental plasticity in the T helper 17 lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

CD4+ T cell plasticity-Th2 cells join the crowd.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Plasticity of CD4+ T cell lineage differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Interleukin-23 is critical for full-blown expression of a non-autoimmune destructive arthritis and regulates interleukin-17A and RORgammat in gammadelta T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

The biology of CD20 and its potential as a target for mAb therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Ocrelizumab: a step forward in the evolution of B-cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

T cell co-stimulation and in vivo tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

CTLA4-Ig modifies dendritic cells from mice with collagen-induced arthritis to increase the CD4+CD25+Foxp3+ regulatory T cell population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Janus kinases in immune cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Cytokine/Jak/Stat signaling mediates regeneration and homeostasis in the Drosophila midgut

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Novel small-molecular therapeutics for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Cytokine signaling modules in inflammatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Remission in rheumatoid arthritis: wishful thinking or clinical reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Predictors for remission in rheumatoid arthritis patients: A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Abatacept Limits Breach of Self-Tolerance in a Murine Model of Arthritis via Effects on the Generation of T Follicular Helper Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Immunology. Regulating suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

CTLA-4IG suppresses reactive oxygen species by preventing synovial adherent cell-induced inactivation of Rap1, a Ras family GTPASE mediator of oxidative stress in rheumatoid arthritis T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Biologics for rheumatoid arthritis: an overview of Cochrane reviews.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Mechanisms of inflammation in gout

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

B lymphocyte depletion in rheumatoid arthritis: targeting of CD20

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Long-term amelioration of established collagen-induced arthritis achieved with short-term therapy combining anti-CD3 and anti-tumor necrosis factor treatments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.8

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

31 March 2020

1 reference

12 December 2020

Targeting CD22 as a strategy for treating systemic autoimmune diseases

1 reference

12 December 2020

Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis

1 reference

12 December 2020

Clinical and immunologic effects of a PRIMATIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis: results of a phase I, single dose, dose escalating trial.

1 reference

12 December 2020

Updates from B Cell Trials: Efficacy.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2013.8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23419427%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

24 February 2020

1051368002

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23419427%20AND%20SRC:MED&resulttype=core&format=json